15 March 2012 – Parsortix update
Another important milestone has been achieved by Parsortix with the news that its blood cell separation device can capture colon cancer cells. This follows the earlier successes with breast cancer, lung cancer and prostrate cancer. This is further good news for ANGLE, which owns 90% of Parsortix. Despite this morning’s rise in the company’s share price, the shares are a buy having fallen from 95p last October. BUY.